# KaliVir Immunotherapeutics


## Posts

- [KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial](https://kalivir.com/kalivir-immunotherapeutics-reports-71-objective-response-rate-in-patients-with-advanced-cutaneous-malignancies-in-phase-1-1b-stealth-001-trial/)
- [KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing](https://kalivir.com/kalivir-immunotherapeutics-announces-closing-of-14-million-series-a-extension-financing/)
- [KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-vet3-tgi-in-combination-with-atezolizumab-tecentriq-in-advanced-solid-tumors/)
- [KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-announces-completion-of-first-intravenous-patient-cohort-of-stealth-001-study-evaluating-vet3-tgi-in-patients-with-advanced-solid-tumors/)
- [KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-announces-completion-of-first-cohort-of-stealth-001-study-evaluating-vet3-tgi-in-patients-with-advanced-solid-tumors/)
- [KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting/)
- [KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates](https://kalivir.com/kalivir-immunotherapeutics-strengthens-innovation-portfolio-with-issuance-of-three-new-u-s-patents-covering-its-vet-product-candidates/)
- [KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-doses-first-patient-in-phase-1-1b-trial-of-vet3-tgi-for-incurable-advanced-solid-tumors/)
- [KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer](https://kalivir.com/kalivir-immunotherapeutics-appoints-schond-greenway-as-chief-financial-officer/)
- [KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors/)
- [KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer](https://kalivir.com/kalivir-immunotherapeutics-appoints-james-m-burke-m-d-as-chief-medical-officer/)
- [KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses](https://kalivir.com/kalivir-announces-opening-of-gmp-cleanroom-facility-increasing-manufacturing-capacity-for-oncolytic-viruses/)
- [KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors](https://kalivir.com/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-systemic-oncolytic-virus-asp1012-for-phase-i-clinical-trials-for-locally-advanced-or-metastatic-solid-tumors/)
- [KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-announces-new-in-vivo-data-demonstrating-superior-therapeutic-efficacy-of-vet3-tgi-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting/)
- [KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors](https://kalivir.com/kalivir-immunotherapeutics-appoints-viral-immunotherapy-researcher-grant-mcfadden-ph-d-to-its-board-of-directors/)
- [KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-announces-presentation-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting/)
- [KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-announces-new-in-vivo-data-demonstrating-potent-therapeutic-activity-for-oncolytic-therapy-vet3-tgi-at-the-american-association-for-cancer-research-aacr-annual-meeting/)
- [KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards](https://kalivir.com/kalivir-immunotherapeutics-establishes-clinical-and-scientific-advisory-boards/)
- [KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-announces-pre-clinical-data-for-oncolytic-therapy-vet3-tgi-at-the-society-for-immunology-of-cancer-sitc-37th-annual-meeting/)
- [KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline](https://kalivir.com/kalivir-appoints-industry-veteran-adina-pelusio-as-senior-vice-president-of-clinical-operations-to-lead-clinical-development-pipeline/)
- [KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)](https://kalivir.com/kalivir-immunotherapeutics-to-present-at-14th-international-oncolytic-virotherapy-conference-iovc/)
- [KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting](https://kalivir.com/kalivir-immunotherapeutics-to-present-data-on-its-novel-pre-clinical-oncolytic-therapy-vet3-tgi-at-the-society-for-immunology-of-cancer-sitc-annual-meeting/)
- [KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses](https://kalivir.com/kalivir-immunotherapeutics-enters-into-global-exclusive-licensing-agreement-with-roche-for-novel-oncolytic-viruses/)
- [KaliVir Immunotherapeutics Closes Series A Financing](https://kalivir.com/kalivir-immunotherapeutics-closes-series-a-financing/)
- [KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.](https://kalivir.com/kalivir-immunotherapeutics-strengthens-intellectual-property-position-through-issuance-of-two-u-s-patents/)
- [KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors](https://kalivir.com/kalivir-immunotherapeutics-appoints-drs-terry-hermiston-and-jon-wigginton-to-board-of-directors/)
- [KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.](https://kalivir.com/kalivir-immunotherapeutics-and-astellas-enter-worldwide-exclusive-licensing-agreement-for-development-and-commercialization-of-vet2-l2-novel-oncolytic-virus/)
- [How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies](https://kalivir.com/how-stephen-thorne-and-helena-chaye-are-blending-their-talents-to-create-breakthrough-cancer-fighting-therapies/)

## Pages

- [Cookie Policy](https://kalivir.com/cookie-policy/): This Cookie Policy explains how KaliVir Immunotherapeutics, Inc. (“KaliVir”) uses cookies and similar technologies on this website.
- [Terms of Use](https://kalivir.com/terms-of-use/): Welcome to the website of KaliVir Immunotherapeutics, Inc. (“KaliVir”). By accessing or using this website, you agree to these Terms of Use.
- [Privacy Policy](https://kalivir.com/privacy-policy/): This Privacy Policy explains how KaliVir Immunotherapeutics, Inc.
- [Presentations](https://kalivir.com/presentations/)
- [Publications](https://kalivir.com/publications/)
- [News](https://kalivir.com/news/)
- [STEALTH-001 Trial](https://kalivir.com/stealth-001/): A Phase 1/1b study of VET3-TGI given alone and with atezolizumab in patients with advanced solid tumors.
- [Pipeline](https://kalivir.com/pipeline/)
- [Our Science](https://kalivir.com/science/): Our Vaccinia Enhanced Template (VET™) platform enables the engineering of tumor-selective oncolytic vaccinia viruses with targeted delivery capabilities and diverse therapeutic payloads.
- [Our Company](https://kalivir.com/company/): A clinical-stage company advancing a differentiated, multi-mechanistic oncolytic immunotherapy for cancers that resist checkpoint inhibitors.
- [Home](https://kalivir.com/): KaliVir is developing VET3-TGI, a multi-mechanistic oncolytic immunotherapy engineered to overcome immune resistance in cancers that no longer respond to checkpoint inhibitors.


[comment]: # (Generated by Hostinger Tools Plugin)